In particular, alterations in RGS6 signaling and/or expression have been associated with: alcohol use disorders (rs11621871; Stewart et al., 2015; Chen et al., 2017), anxiety/depression (Stewart et al., 2014), Parkinson’s disease (Bifsha et al., 2014; Luo et al., 2019; Petyuk et al., 2021), Alzheimer’s disease (rs4899412; Moon et al., 2015), motor coordination (Maity et al., 2012), adult hippocampal neurogenesis (Gao et al., 2020), as well as human cataracts, mental retardation, and microcephaly (c. Here, RGS6 is linked to depressive symptom measurement.